SG11202004801WA - A conjugate of a tubulysin analog with branched linkers - Google Patents
A conjugate of a tubulysin analog with branched linkersInfo
- Publication number
- SG11202004801WA SG11202004801WA SG11202004801WA SG11202004801WA SG11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA SG 11202004801W A SG11202004801W A SG 11202004801WA
- Authority
- SG
- Singapore
- Prior art keywords
- conjugate
- branched linkers
- tubulysin analog
- tubulysin
- analog
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/120454 WO2019127607A1 (en) | 2017-12-31 | 2017-12-31 | A conjugate of a tubulysin analog with branched linkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004801WA true SG11202004801WA (en) | 2020-06-29 |
Family
ID=67064953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004801WA SG11202004801WA (en) | 2017-12-31 | 2017-12-31 | A conjugate of a tubulysin analog with branched linkers |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20200276261A1 (en) |
| EP (1) | EP3621652A4 (en) |
| JP (2) | JP7262817B2 (en) |
| KR (2) | KR102641565B1 (en) |
| CN (1) | CN111093707A (en) |
| AU (2) | AU2017445144A1 (en) |
| BR (1) | BR112020010405A2 (en) |
| CA (1) | CA3085634C (en) |
| CL (1) | CL2020001600A1 (en) |
| EA (1) | EA202091217A1 (en) |
| IL (1) | IL275274A (en) |
| MX (1) | MX2020006192A (en) |
| PH (1) | PH12020550657A1 (en) |
| SG (1) | SG11202004801WA (en) |
| WO (1) | WO2019127607A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11873281B2 (en) | 2012-07-12 | 2024-01-16 | Hangzhou Dac Biotech Co., Ltd. | Conjugates of cell binding molecules with cytotoxic agents |
| DK2872157T3 (en) | 2012-07-12 | 2020-03-30 | Hangzhou Dac Biotech Co Ltd | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| AU2020301115A1 (en) * | 2019-06-24 | 2022-02-10 | Hangzhou Dac Biotech Co., Ltd | A formulation of a conjugate of a tubulysin analog to a cell-binding molecule |
| KR20220024914A (en) * | 2019-06-24 | 2022-03-03 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Conjugate of Cytotoxic Agents to Cell Binding Molecules Using Branched Linkers |
| BR112021025984A2 (en) * | 2019-06-29 | 2022-04-12 | Hangzhou Dac Biotech Co Ltd | Tubulisin b antibody-derived conjugate (analog), compound, pharmaceutical composition, e, uses of the conjugate, compounds and pharmaceutical compositions |
| WO2021022678A1 (en) * | 2019-08-07 | 2021-02-11 | 烟台迈百瑞国际生物医药股份有限公司 | Antibody-drug conjugate and application thereof |
| EP3862023A1 (en) * | 2020-02-05 | 2021-08-11 | Hangzhou DAC Biotech Co, Ltd | Conjugates of cell-binding molecules with cytotoxic agents |
| US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
| CN112138170B (en) * | 2020-09-28 | 2022-05-20 | 广东药科大学 | Conjugate for preventing cisplatin drug-induced deafness and preparation method and application thereof |
| CN112755173B (en) * | 2020-12-31 | 2022-01-07 | 深圳市科达顺生物技术有限公司 | Ii-Key/HER2 hybrid polypeptide medicine for treating triple negative breast cancer and preparation method thereof |
| CN112961060B (en) * | 2021-02-09 | 2022-03-25 | 武汉大学 | Isotope labeled N, N-dimethylethylenediamine, preparation method thereof and analysis method of short-chain fatty acid |
| CN115197297B (en) | 2021-04-14 | 2023-08-01 | 启德医药科技（苏州）有限公司 | Linker, conjugate and uses thereof |
| WO2022266354A1 (en) * | 2021-06-16 | 2022-12-22 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and napoli |
| WO2022078524A2 (en) * | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| WO2023209625A1 (en) * | 2022-04-28 | 2023-11-02 | Scirosbio (Fzc) | Compositions and methods for treatment of cancer |
| WO2023244803A1 (en) * | 2022-06-17 | 2023-12-21 | The Regents Of The University Of California | Methods and compositions comprising tobacco mild green mosaic virus (tmgmv) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776814B2 (en) * | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
| US9555139B2 (en) * | 2007-03-14 | 2017-01-31 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| CN105849086B (en) * | 2012-11-24 | 2018-07-31 | 杭州多禧生物科技有限公司 | Hydrophily chain junctor and its application on drug molecule and cell-binding molecules conjugation reaction |
| CN114262344A (en) * | 2014-02-28 | 2022-04-01 | 杭州多禧生物科技有限公司 | Charged linkers and their use in conjugation reactions |
| CA2945318A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Tubulysin derivatives |
| CN105641707B (en) * | 2014-11-11 | 2020-11-24 | 杭州多禧生物科技有限公司 | Conjugates of cytotoxic molecules and cell-binding receptor molecules |
| CA2989269C (en) | 2015-06-15 | 2020-09-22 | Robert Yongxin Zhao | Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule |
| WO2015155753A2 (en) * | 2015-08-10 | 2015-10-15 | Suzhou M-Conj Biotech Co., Ltd | Novel linkers and their uses in specific conjugation of drugs to a biological molecule |
| EP3411074A4 (en) | 2016-02-04 | 2019-09-04 | Suzhou M-conj Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
| JP7295640B2 (en) * | 2016-04-20 | 2023-06-21 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | Derivatives of amanita toxin and their conjugates with cell binding molecules |
| CN110099682B (en) * | 2016-11-14 | 2023-03-31 | 杭州多禧生物科技有限公司 | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof |
| KR20210122319A (en) * | 2017-04-06 | 2021-10-08 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Conjugation of a cytotoxic drug with bis-linkage |
-
2017
- 2017-12-31 JP JP2020535958A patent/JP7262817B2/en active Active
- 2017-12-31 BR BR112020010405-1A patent/BR112020010405A2/en unknown
- 2017-12-31 KR KR1020237017364A patent/KR102641565B1/en active IP Right Grant
- 2017-12-31 AU AU2017445144A patent/AU2017445144A1/en not_active Abandoned
- 2017-12-31 SG SG11202004801WA patent/SG11202004801WA/en unknown
- 2017-12-31 WO PCT/CN2017/120454 patent/WO2019127607A1/en unknown
- 2017-12-31 CN CN201780094901.3A patent/CN111093707A/en active Pending
- 2017-12-31 KR KR1020207019406A patent/KR102603344B1/en active IP Right Grant
- 2017-12-31 CA CA3085634A patent/CA3085634C/en active Active
- 2017-12-31 US US16/759,175 patent/US20200276261A1/en active Pending
- 2017-12-31 EP EP17936036.7A patent/EP3621652A4/en active Pending
- 2017-12-31 EA EA202091217A patent/EA202091217A1/en unknown
- 2017-12-31 MX MX2020006192A patent/MX2020006192A/en unknown
-
2020
- 2020-05-18 PH PH12020550657A patent/PH12020550657A1/en unknown
- 2020-06-10 IL IL275274A patent/IL275274A/en unknown
- 2020-06-15 CL CL2020001600A patent/CL2020001600A1/en unknown
-
2022
- 2022-07-15 AU AU2022205269A patent/AU2022205269A1/en active Pending
-
2023
- 2023-01-19 US US18/156,709 patent/US20230165930A1/en active Pending
- 2023-01-19 US US18/156,748 patent/US20230165931A1/en active Pending
- 2023-01-19 US US18/156,793 patent/US20230149502A1/en active Pending
- 2023-04-05 JP JP2023061065A patent/JP2023093531A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022205269A1 (en) | 2022-08-11 |
| US20200276261A1 (en) | 2020-09-03 |
| JP2023093531A (en) | 2023-07-04 |
| CA3085634A1 (en) | 2019-07-04 |
| CN111093707A (en) | 2020-05-01 |
| EA202091217A1 (en) | 2020-09-18 |
| KR102603344B1 (en) | 2023-11-16 |
| CA3085634C (en) | 2023-11-14 |
| MX2020006192A (en) | 2020-08-20 |
| CL2020001600A1 (en) | 2021-03-19 |
| US20230165930A1 (en) | 2023-06-01 |
| KR20230075530A (en) | 2023-05-31 |
| KR20200097295A (en) | 2020-08-18 |
| JP7262817B2 (en) | 2023-04-24 |
| EP3621652A1 (en) | 2020-03-18 |
| WO2019127607A1 (en) | 2019-07-04 |
| PH12020550657A1 (en) | 2021-04-19 |
| KR102641565B1 (en) | 2024-02-27 |
| AU2017445144A1 (en) | 2020-06-18 |
| US20230165931A1 (en) | 2023-06-01 |
| US20230149502A1 (en) | 2023-05-18 |
| JP2021507928A (en) | 2021-02-25 |
| BR112020010405A2 (en) | 2020-11-24 |
| IL275274A (en) | 2020-07-30 |
| EP3621652A4 (en) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275274A (en) | A conjugate of a tubulysin analog with branched linkers | |
| IL269713A (en) | Conjugation of a cytotoxic drug with bis-linkage | |
| ZA202003833B (en) | Conjugates and preparation and use thereof | |
| IL273471B1 (en) | Antibody-pyrrolobenzodiazepine derivative conjugate | |
| EP3380126A4 (en) | Antibody-drug conjugates comprising branched linkers and methods related thereto | |
| IL266310A (en) | Peptide-containing linkers for antibody-drug conjugates | |
| SI3592393T1 (en) | Releasable conjugates | |
| IL282182A (en) | Conjugation of a cytotoxic drug with bis-linkage | |
| IL273084A (en) | Auscultation of a body | |
| SG11202007919RA (en) | Antibody-drug conjugate having acidic self-stabilization junction | |
| EP3501548A4 (en) | Tissue factor-targeted antibody-drug conjugate | |
| IL254258A0 (en) | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers | |
| HUE056376T2 (en) | Novel hydrophilic linkers and ligand-drug conjugates thereof | |
| IL268921B (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
| EP3668838A4 (en) | Tetramaleimide linkers and use thereof | |
| IL284007A (en) | Rifamycin analogs and antibody-drug conjugates thereof | |
| SG11202104993SA (en) | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate | |
| IL283682A (en) | Linkers | |
| FI3666787T3 (en) | Antibody-drug conjugates including hemiasterlin derivative | |
| IL269321A (en) | Drug-polymer conjugate | |
| GB201615725D0 (en) | Novel cytotoxic agents and conjugates thereof | |
| PL3566674T3 (en) | Digitizable dental implant analog | |
| GB201710097D0 (en) | A sensitizer - peptide conjugate | |
| GB201713700D0 (en) | Peptide conjugates | |
| IL271968A (en) | Adjustable vascular ring and implantable kit comprising such a ring |